Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.
It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.
During the 2009 H1N1 influenza pandemic, many previously healthy children became critically ill, developing severe pneumonia and respiratory failure, sometimes fatal. The largest nationwide investigation to date of influenza in critically ill children, led by Children's Hospital Boston, found one key risk factor: Simultaneous infection with methicillin-resistant Staphylococcus aureus (MRSA) increased the risk for flu-related mortality 8-fold among previously healthy children.
Financial strain and competing priorities at home may contribute to the greater number of hospital readmissions of children with asthma from single-parent homes compared to dual-parent households, according to a new study presented at the American College of Allergy, Asthma and Immunology Annual Meeting in Boston, Nov. 3-8.
Guided by insights into how mice recover after H1N1 flu, researchers at Harvard Medical School and Brigham and Women's Hospital, together with researchers at A*STAR of Singapore, have cloned three distinct stem cells from the human airways and demonstrated that one of these cells can form into the lung's alveoli air sac tissue.
According to a report published online October 25 in The Lancet Infectious Diseases there are gaps in the evidence for the effectiveness of licensed influenza vaccines in the United States. Individuals who are at risk for medical complications or people who are aged 65 years or older are especially affected by the gaps, the researchers write.
The pivotal pediatric clinical study compared Q/LAIV to two trivalent formulations of MedImmune's licensed seasonal influenza vaccine, FluMist (Influenza Vaccine Live, Intranasal) and met its primary endpoint.
Sanofi Pasteur, the vaccines division of Sanofi, announced today the results of a new study evaluating the immunogenicity and safety of an investigational quadrivalent inactivated influenza vaccine (QIV) among adults 65 years of age and older.
Romark Laboratories announced that results of a large Phase 2B-3 US clinical trial of its new flu drug, NT-300 (nitazoxanide), will be presented as an oral late-breaking communication at the 49th Annual Meeting of the Infectious Diseases Society of America (IDSA) being held in Boston, October 20-23, 2011.
NanoViricides, Inc. announced that its President, Dr. Anil Diwan, has completed the programmed sale of the NanoViricides stock that he had obtained as a founder.
A unique and innovative analysis of how social media can affect the spread of a disease has been designed and implemented by a scientist at Penn State University studying attitudes toward the H1N1 vaccine. Marcel Salath-, an assistant professor of biology, studied how users of Twitter -- a popular microblogging and social-networking service -- expressed their sentiments about a new vaccine.
Building on the success of Louisville's response to the 2009 H1N1 influenza pandemic, Ruth Carrico, PhD, plans to use a $250,000 one-year cooperative agreement from the Centers for Disease Control and Prevention (CDC) to create an emergency countermeasure staffing plan that utilizes nursing, pharmacy and public health students.
CEL-SCI Corporation announced today that it has closed its previously announced registered direct offering for the sale of (i) 13,333,334 shares of its common stock at a price per share of $0.30 and (ii) warrants to purchase up to 12,000,000 shares of CEL-SCI Corporation's common stock at a purchase price of $0.40. The warrants may be exercised at any time prior to October 6, 2014.
According to a new study some parents choose alternative schedules for vaccinating their children and yet others decide their own vaccine timelines.
The immune response to an H5N1 avian influenza vaccine was greatly enhanced in healthy adults if they were first primed with a DNA vaccine expressing a gene for a key H5N1 protein, researchers say.
For most people, the flu is a temporary setback that makes them feel under the weather for a week or two. For dialysis patients with kidney failure, however, the flu is a serious health threat that can lead to pneumonia and other life-threatening complications.
Last week, the U.S. Army Office of the Surgeon General received Food and Drug Administration (FDA) clearance of two Influenza test kits for use on the Joint Biological Agent Identification and Diagnostic System.
October marks the beginning of flu season, and once again, health care professionals are exhorting people to get a flu shot. Microbiologist John Tudor, Ph.D., professor of biology at Saint Joseph's University in Philadelphia, agrees that it's time to roll up our sleeves and offer up our arms for the vaccination.
People with asthma who are admitted to hospital with pandemic influenza H1N1 (swine flu) are half as likely to die or require intensive care than those without asthma, according to new research.
Britain’s National Health Service (NHS) is urging its staff to take their flu shots amid fresh warnings that low vaccination rates among health professionals could lead to vulnerable patients getting infected and dying. The NHS's employers, health trade unions and the Department of Health have launched a campaign to tackle low immunization rates among frontline staff such as doctors and nurses.
As temperatures begin to cool, coughing and sneezing inevitably follow. So begins flu season in the United States — and preventable deaths, says David Kimberlin, M.D., University of Alabama at Birmingham professor of pediatrics and president-elect of the Pediatric Infectious Diseases Society.
NanoViricides, Inc. announced that Inno-Haven LLC has completed acquisition of a light industrial building. The Company anticipates that it will be leasing a portion of this space, in the near future, for laboratory facilities and cGMP production of its nanoviricides® drug candidates against various viral diseases.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.